{"disease":{"id":"shigellosis","name":"Shigellosis","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":9,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"sulfamethoxazole","indication_name":"Shigellosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Azo Gantanol","generic_name":"SULFAMETHOXAZOLE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"Sulfonamide Antimicrobial [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"ampicillin","indication_name":"Shigellosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Unasyn","generic_name":"AMPICILLIN","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Transient receptor potential cation channel subfamily M member 4","drug_class":"Penicillin-class Antibacterial","quality_score":53,"revenue":null,"mechanism":""},{"drug_id":"trimethoprim","indication_name":"Shigellosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Trimethoprim","generic_name":"TRIMETHOPRIM","company_name":"Dr Reddys Labs Sa","drug_phase":"marketed","molecular_target":"Dihydrofolate reductase","drug_class":"Sulfonamide Antimicrobial [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"sulfamethizole","indication_name":"Shigellosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sulfurine","generic_name":"SULFAMETHIZOLE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"sulfamethizole","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"ciprofloxacine","indication_name":"Shigellosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ciprofloxacine","company_name":"Poitiers University Hospital","drug_phase":"discontinued","molecular_target":"DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"norfloxacin","indication_name":"Shigellosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Noroxin","generic_name":"NORFLOXACIN","company_name":"","drug_phase":"marketed","molecular_target":"Gamma-aminobutyric acid receptor subunit alpha-1","drug_class":"Quinolone Antimicrobial","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"ofloxacin","indication_name":"Shigellosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Floxin","generic_name":"OFLOXACIN","company_name":"","drug_phase":"marketed","molecular_target":"Histamine H3 receptor","drug_class":"Quinolone Antimicrobial [EPC]","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"ciprofloxacin","indication_name":"Shigellosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cipro","generic_name":"ciprofloxacin","company_name":"Bayer AG","drug_phase":"marketed","molecular_target":"DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A","drug_class":"Fluoroquinolone antibiotic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"ofloxacine","indication_name":"Shigellosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ofloxacine","company_name":"Assistance Publique - Hôpitaux de Paris","drug_phase":"phase_3","molecular_target":"Gamma-aminobutyric acid receptor subunit alpha-2, Histamine H3 receptor, Muscarinic acetylcholine receptor M1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":9,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05156528","title":"Efficacy, Immunogenicity and Safety of S. Flexneriza-S. Sonnei Bivalent Conjugate Vaccine in Volunteers Aged From 6 Months to 5 Years","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":21000,"lead_sponsor_name":"Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd","has_results":false},{"nct_id":"NCT04056117","title":"A Study to Determine If a New Shigella Vaccine is Safe, Induces Immunity and The Best Dose Among Kenyan Infants","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":596,"lead_sponsor_name":"LimmaTech Biologics AG","has_results":false},{"nct_id":"NCT03854929","title":"Ciprofloxacin Versus Azithromycin for Children Hospitalised With Dysentery","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":364,"lead_sponsor_name":"Oxford University Clinical Research Unit, Vietnam","has_results":false},{"nct_id":"NCT05121974","title":"Tebipenem Trial in Children With Shigellosis","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":132,"lead_sponsor_name":"International Centre for Diarrhoeal Disease Research, Bangladesh","has_results":false},{"nct_id":"NCT06523231","title":"Study to Expand Safety and Immunogenicity Data With Shigella Bioconjugate Vaccine (Shigella4V2) in 9-month-old Infants.","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":110,"lead_sponsor_name":"LimmaTech Biologics AG","has_results":false},{"nct_id":"NCT05959616","title":"Shigella Sonnei 53G Human Infection Study in Kenyan Adults","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":70,"lead_sponsor_name":"University of Oxford","has_results":false},{"nct_id":"NCT01369927","title":"Shigella Sonnel O-SPC/rBRU Conjugate Vaccine","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","has_results":false},{"nct_id":"NCT05182749","title":"Safety and Efficacy of the Bacteriophage Preparation, ShigActive™, in a Human Experimental Model of Shigellosis","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":52,"lead_sponsor_name":"Intralytix, Inc.","has_results":false},{"nct_id":"NCT04992520","title":"Controlled Human Infection Model Challenge/Rechallenge","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":46,"lead_sponsor_name":"PATH","has_results":true},{"nct_id":"NCT02445963","title":"Safety and Immunogenicity of Artificial Invaplex (Shigella Flexneri 2a InvaplexAR)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":38,"lead_sponsor_name":"U.S. Army Medical Research and Development Command","has_results":true},{"nct_id":"NCT01399424","title":"Shigella Sonnei OSPC-rDT Conjugate Vaccine","phase":"PHASE1","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","has_results":false}],"total":11},"guidelines":[],"source":"Drug Landscape verified database"}